Blog

Novartis, Roche back French gene therapy start-up Vivet – WHTC


Endpoints News

Novartis, Roche back French gene therapy start-up Vivet
WHTC
(Reuters) – French gene therapy start-up Vivet Therapeutics said on Thursday it had raised 37.5 million euros ($41 million) in an initial financing round, with backing from the venture arms of Swiss drugmakers Novartis and Roche. Other investors
GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotechEndpoints News


Vivet Therapeutics Raises €37.5 Million in Series A Financing Round to Advance Novel Gene Therapies for Treating …PR Newswire (press release)

all 4 news articles »

2017-05-04 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.